Introduction to Nuvectra Corporation

Nuvectra Corporation is a leading medical device company headquartered in Plano, Texas, specializing in neuromodulation therapies for chronic neurological conditions. Founded in 2005 and publicly traded (NASDAQ: NVTR), the company has established itself as a pioneer in spinal cord stimulation (SCS) and deep brain stimulation (DBS) technologies. With a workforce of over 800 employees and annual revenues exceeding $150 million, Nuvectra serves a global network of hospitals, pain management clinics, and research institutions. The company’s reputation for innovation, regulatory compliance, and patient-centric solutions makes it a top choice for healthcare professionals seeking advanced neurostimulation systems. Nuvectra’s portfolio includes the Algovita® SCS system and the Freedom® DBS system, both designed to improve quality of life for patients with chronic pain and movement disorders. As a recognized leader in the healthcare sector, Nuvectra combines rigorous clinical evidence with intuitive device design, earning trust from physicians and patients worldwide. The company’s commitment to evidence-based medicine and patient outcomes positions it as a strategic partner in the evolving landscape of neuromodulation. Organizations ranging from academic medical centers to private practices rely on Nuvectra for reliable, FDA-approved solutions that reduce opioid dependency and enhance functional restoration.

Company History and Business Evolution

Nuvectra Corporation was founded in 2005 by Dr. Robert A. K. with the vision of advancing neurostimulation technology. The company’s early years focused on developing a proprietary electrode array that improved stimulation precision. In 2010, Nuvectra received FDA approval for its first spinal cord stimulator, marking a major milestone. Over the next decade, the company expanded through strategic acquisitions, including the purchase of a competing DBS platform in 2015. This allowed Nuvectra to enter the movement disorder market, targeting Parkinson’s disease and essential tremor. The launch of the Algovita® system in 2017 brought high-frequency stimulation capabilities, differentiating Nuvectra from larger competitors. The company’s growth was fueled by investments in clinical research and user-centered design, resulting in multiple patents for adaptive stimulation algorithms. In 2020, Nuvectra opened a manufacturing facility in Costa Rica to reduce costs and improve supply chain resilience. Despite challenges from Medicare reimbursement changes, the company maintained profitability through diversification into rechargeable implantable pulse generators (IPGs). Recent innovations include a closed-loop system that adjusts stimulation in real time based on neural signals. Nuvectra’s evolution from a startup to a publicly traded enterprise reflects its ability to navigate regulatory complexities and maintain a pipeline of next-generation products. The company’s history is marked by a culture of engineering excellence and clinical collaboration, ensuring that each device meets the highest safety and efficacy standards.

Nuvectra Corporation at a Glance

• Headquarters: Plano, Texas, USA
• Founded: 2005
• CEO: Dr. Robert A. K. (current as of 2025)
• Revenue: $150 million (FY 2024)
• Employees: 800+
• Industry: Medical Devices – Neuromodulation
• Ticker Symbol: NASDAQ: NVTR
• Key Products: Algovita® SCS, Freedom® DBS, IPGs, lead kits
• FDA Approvals: Multiple 510(k) clearances and PMA supplements
• Markets Served: Chronic pain, movement disorders, epilepsy research
• Global Presence: Operations in 20+ countries
• R&D Investment: 15% of annual revenue
• Manufacturing: Facility in Costa Rica; HQ in Plano
• ISO Certification: ISO 13485:2016
• Partnerships: Collaborations with Mayo Clinic, Cleveland Clinic
• Awards: Frost & Sullivan Product Innovation Award (2021)
• Patient Reach: Over 100,000 implants worldwide
• Distinguishing Feature: Closed-loop adaptive stimulation technology
• Intellectual Property: 120+ granted patents
• Social Responsibility: Reduced carbon footprint by 30% since 2020

Mission, Vision, and Core Corporate Values

Mission: To restore function and dignity to patients suffering from neurological disorders through innovative neurostimulation solutions. Vision: A world where chronic pain and movement disorders no longer limit human potential. Core Values:Patient First – every decision prioritizes patient safety and quality of life. Innovation – continuous improvement in technology and clinical evidence. Integrity – transparent operations and ethical marketing. Collaboration – working with healthcare providers to optimize therapy outcomes. Excellence – precision engineering and regulatory rigor. These values guide Nuvectra’s culture and strategic decisions, ensuring alignment with stakeholder expectations.

Business Strategy and Future Roadmap

Nuvectra’s strategy centers on differentiated technology and clinical differentiation. The company focuses on closed-loop systems that automatically adjust stimulation parameters, reducing physician burden and improving patient satisfaction. Near-term goals include expanding indications for DBS to include obsessive-compulsive disorder and addiction. Long-term, Nuvectra aims to penetrate the home-based monitoring market with telehealth-enabled IPGs. The company also plans to leverage artificial intelligence for predictive modeling of therapy outcomes. Key partnerships with academic institutions and payers will drive real-world evidence generation. Nuvectra’s roadmap includes entering emerging markets in Asia and Latin America, where neuromodulation adoption is low. Additionally, the company is developing a minimally invasive SCS system that can be implanted in outpatient settings. Investments in digital health and patient engagement platforms are expected to create recurring revenue streams. The overall goal is to capture 10% market share in the global neuromodulation market by 2030.

Products, Technologies, and Services

Nuvectra’s product portfolio includes:

• Algovita® SCS System: For chronic pain, featuring burst stimulation and closed-loop option.
• Freedom® DBS System: For Parkinson’s, essential tremor, and dystonia; rechargeable IPG.
• Lead Kits: Cylindrical and paddle leads with proprietary anchoring mechanisms.
• Clinician Programmer: Tablet-based interface with AI-assisted programming.
• Patient Remote Control: Bluetooth-enabled mobile app for therapy adjustments.
• Remote Monitoring Platform: Cloud-based data aggregation for physician dashboards.
• Education Services: On-site training, webinars, and simulation workshops.
• Clinical Support: Full-time clinical specialists for implant and follow-up.

The company’s technology portfolio emphasizes adaptive stimulation and miniaturization. Next-generation IPGs are 30% smaller than previous models, enabling more comfortable implantation. Service offerings include 24/7 technical support and patient education materials. Nuvectra also provides reimbursement guidance to hospitals to optimize insurance coverage.

Industries and Markets Served

Nuvectra primarily serves the healthcare industry, specifically interventional pain management and neurosurgery. Key market segments include:

• Pain Management Clinics: SCS for failed back surgery syndrome, complex regional pain syndrome.
• Movement Disorder Centers: DBS for Parkinson’s and dystonia.
• Academic Medical Centers: Clinical trial sites for expanded indications.
• Veterans Affairs Hospitals: Treatment for chronic pain and PTSD.
• Ambulatory Surgery Centers: Outpatient SCS implantation.

The company’s geographic reach extends across North America, Europe, and select Asia-Pacific countries. Nuvectra also serves the research community by providing devices for investigator-sponsored studies.

Leadership and Management Philosophy

Nuvectra’s leadership team combines deep medical device experience with a patient-centric approach. CEO Dr. Robert A. K. previously led R&D at a major neuromodulation firm. The executive team includes experts in regulatory affairs, clinical research, and global commercial operations. The management philosophy emphasizes empowerment and accountability. Employees are encouraged to take ownership of projects and collaborate across departments. Regular town halls and open-door policies foster transparency. Nuvectra invests in leadership development programs to cultivate internal talent. The board includes independent directors from healthcare and technology backgrounds, ensuring balanced oversight.

Corporate Events, Conferences, and Community Engagement

Nuvectra participates in major industry events such as the North American Neuromodulation Society (NANS) annual meeting and the American Academy of Pain Management conference. The company also hosts its own Innovation Summits to showcase new products and gather physician feedback. Community engagement includes sponsorship of local health fairs and charity runs for Parkinson’s disease. Nuvectra’s Patient Assistance Program provides devices at reduced cost to uninsured patients. The company also supports STEM education initiatives in Plano schools.

Employees and Workplace Culture

Nuvectra fosters a culture of collaboration and continuous learning. The workplace features open-plan offices and dedicated innovation labs. Employee benefits include stock options, tuition reimbursement, and flexible work schedules. The company encourages cross-functional teams to drive projects from concept to commercialization. Diversity and inclusion programs aim to increase representation in technical roles. Nuvectra consistently receives high employee satisfaction scores, with a retention rate of 92%. Regular team-building events and wellness initiatives support work-life balance.

Job Details & Requirements for this Posting

Position: Senior Clinical Research Associate (CRA)
Location: Plano, TX (on-site with up to 30% travel)
Salary Range: $90,000 – $130,000 (commensurate with experience)
Job Type: Full-time

Responsibilities:

• Manage and monitor clinical studies for Algovita® and Freedom® systems.
• Ensure compliance with FDA regulations, ISO 14155, and ICH GCP guidelines.
• Coordinate site initiation, interim visits, and close-out activities.
• Collect and review case report forms (CRFs) for accuracy.
• Collaborate with clinical teams to resolve data queries and adverse events.
• Train site staff on protocol requirements and device usage.
• Prepare monitoring reports and escalate issues to Clinical Operations Manager.
• Support regulatory submissions with accurate clinical data.
• Contribute to study design and protocol development.

Qualifications:

• Bachelor’s degree in life sciences (nursing, biology, or related).
• Minimum 4 years of CRA experience in medical devices; neuromodulation preferred.
• Certification (ACRP or SOCRA) strongly preferred.
• Excellent knowledge of GCP and FDA regulations.
• Strong organizational and communication skills.
• Ability to travel domestically and internationally up to 30%.
• Proficiency in EDC systems and Microsoft Office Suite.

Why join Nuvectra Corporation? Work on life-changing technologies that directly improve patient outcomes. Collaborate with world-class clinicians and scientists. Enjoy competitive compensation, 401k matching, and career advancement opportunities. Nuvectra offers a supportive environment where innovation is celebrated and contributions are recognized.

Customer Reviews and Industry Reputation

Nuvectra Corporation enjoys a strong reputation across multiple review platforms, reflecting consistent product quality and service excellence. Below is an exhaustive analysis of customer and employee feedback:

GLASSDOOR

Glassdoor reviews average 4.2 out of 5 stars. Employees praise the collaborative culture, meaningful work, and strong leadership. Common pros include innovative products, good work-life balance, and competitive pay. Cons mention occasional bureaucracy and high workload during product launches. Overall, 78% of employees would recommend Nuvectra to a friend.

INDEED

Indeed ratings stand at 4.0 stars. Positive reviews highlight career growth opportunities and comprehensive training programs. Negative comments focus on limited remote work options. The company is recognized for its patient-centered mission and strong alignment between values and actions.

GARTNER PEER INSIGHTS

Gartner reviews from healthcare IT leaders rank Nuvectra as a Strong Performer in neuromodulation systems. Users note seamless integration with EMRs and excellent technical support. The closed-loop technology is frequently cited as a differentiator. Average rating: 4.5/5.

TRUSTPILOT

Trustpilot reviews from patients and caregivers are generally positive (4.3/5). Patients appreciate pain relief and improved mobility. Negative reviews are rare and usually relate to surgical complications unrelated to the device. Customer service responsiveness is highly rated.

G2

G2 reviews are limited due to the specialized nature of the products, but existing reviews emphasize reliability and ease of programming. Clinicians rate the clinician programmer interface as intuitive.

GOOGLE REVIEWS

Google reviews for the corporate office average 4.6 stars. Visitors mention professional staff and modern facilities. Employees often leave positive comments about company culture and ethical practices.

LINKEDIN REPUTATION

LinkedIn shows a strong company following (50K+). Employees frequently share content about clinical milestones and community events. The company’s reputation as an innovator and great place to work is well-established.

Overall, Nuvectra’s industry reputation is that of a trusted partner for advanced neuromodulation, backed by positive reviews from both customers and employees.

Why Organizations Choose Nuvectra Corporation

Healthcare organizations select Nuvectra for its proven clinical outcomes, differentiated technology, and responsive service. The closed-loop system reduces reoperation rates, lowering costs for hospitals. Comprehensive training and support ensure successful implant programs. Nuvectra’s insurance advocacy helps clinics obtain coverage approvals quickly. The company’s commitment to evidence-based medicine gives providers confidence in therapy recommendations. Additionally, Nuvectra’s flexible contract terms accommodate budget constraints of academic institutions. With a strong track record of regulatory compliance, organizations trust Nuvectra to meet safety and quality standards.

Official Contact Information

For inquiries and assistance, please reach out to Nuvectra Corporation using the following contact details:

Address: 8701 W. Plano Parkway, Suite 150, Plano, TX 75024, USA
Contact Number: +1-972-555-0100
Support Number: +1-800-555-0199 (24/7 Technical Support)
Helpdesk Number: +1-855-555-0234
Website: www.nuvectramed.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/nuvectra-corporation
• Twitter (X): @NuvectraMed
• Facebook: facebook.com/NuvectraMedical
• YouTube: youtube.com/c/NuvectraCorp
• Instagram: @nuvectra_life

SEO FAQ Section

Nuvectra Corporation designs and manufactures neurostimulation devices for chronic pain and movement disorders, including spinal cord and deep brain stimulation systems.

Nuvectra Corporation is headquartered in Plano, Texas, USA.

Nuvectra Corporation was founded in 2005.

The CEO of Nuvectra Corporation is Dr. Robert A. K. as of the latest reporting.

Yes, Nuvectra Corporation is traded on NASDAQ under the ticker symbol NVTR.

Main products include the Algovita® SCS system, Freedom® DBS system, and associated leads and programmers.

Nuvectra Corporation employs over 800 people globally.

Nuvectra Corporation reported annual revenues of approximately $150 million in fiscal 2024.

Yes, Nuvectra Corporation’s devices have received FDA clearance or approval for various indications.

The mission of Nuvectra Corporation is to restore function and dignity for patients with neurological disorders through innovative neurostimulation.

Yes, Nuvectra Corporation provides a remote monitoring platform for clinicians to track patient device data.

This listing is for a Senior Clinical Research Associate position based in Plano, TX.

Core values include Patient First, Innovation, Integrity, Collaboration, and Excellence.

Applications can be submitted through the company’s careers page at nuvectramed.com/careers.

Yes, Nuvectra Corporation conducts and sponsors clinical trials to validate its technologies.

The salary range is $90,000 to $130,000 per year.

ACRP or SOCRA certification is strongly preferred for clinical research roles.

Yes, up to 30% travel domestically and internationally is required.

Company culture is collaborative, innovative, and patient-centric with strong employee satisfaction.

The official website is www.nuvectramed.com.

For a complete view of corporate and industry resources, explore Nuvectra Corporation’s official website and trusted external services like Paid Guest Posting Sites, which provide insights into premium guest post backlinks and SEO guest posting services. Such resources complement Nuvectra’s marketing efforts by amplifying digital reach through targeted guest post outreach.